Synovial Sarcoma, X Breakpoint 7 (SSX7) Peptide
SSX7
Reactivité: Mammifères
Hôte: Synthetic
BP, WB, IHC
N° du produit ABIN939345
382,12 €
Plus frais de livraison 40,00 € et TVA
100 μg
Destination:
France
Envoi sous 20 à 27 jours ouvrables
Aperçu rapide pour Synovial Sarcoma, X Breakpoint 7 (SSX7) Peptide (ABIN939345)
Antigène
SSX7
(Synovial Sarcoma, X Breakpoint 7 (SSX7))
Origine
Mammifères
Source
Synthetic
Application
Blocking Peptide (BP), Western Blotting (WB), Immunohistochemistry (IHC)
-
-
Type de proteíne
- Synthetic
-
Séquence
- IFPKIMPKKP AEEGNDSKGV PEASGSQNDG KHLCPPGKPS TSEKINKTSG
-
Attributs du produit
-
A synthetic peptide for use as a blocking control in assays to test for specificity of SSX7 antibody,
Alternative Names: SSX7 control peptide, SSX7 antibody Blocking Peptide, Anti-SSX7 Blocking Peptide, synovial sarcoma, X breakpoint 7 Blocking Peptide, SSX7, SSX-7, SSX 7, SSX-7 Blocking Peptide, SSX 7 Blocking Peptide
-
-
-
-
Indications d'application
- Optimal conditions should be determined by the investigator
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Add 100 µL of distilled water for a final peptide concentration is 1 mg/mL.
-
Buffer
- PBS
-
Conseil sur la manipulation
- Avoid repeated freeze/thaw cycles.
-
Stock
- -20 °C
-
Stockage commentaire
- Store at -20 °C long term.
-
-
- SSX7 (Synovial Sarcoma, X Breakpoint 7 (SSX7))
-
Sujet
- SSX7 belongs to the family of highly homologous synovial sarcoma X (SSX) breakpoint proteins. These proteins may function as transcriptional repressors. They are also capable of eliciting spontaneously humoral and cellular immune responses in cancer patients, and are potentially useful targets in cancer vaccine-based immunotherapy. SSX1, SSX2 and SSX4 genes have been involved in the t(X,18) translocation characteristically found in all synovial sarcomas.
-
Poids moléculaire
- 21 kDa
Antigène
-
Vous êtes ici:
